Table 2.
Patient demographics
| Sex (no.) | |
| Male | 25 (59.5%) |
| Female | 17 (40.5%) |
| Median age | 59.5 yrs. (38–81) |
| Imaging pattern on WB-MRI (no.) | |
| Focal | 25 (59.5%) |
| Diffuse | 5 (11.9%) |
| Focal and diffuse | 5 (11.9%) |
| Salt and pepper | 7 (16.7%) |
| Heavy chain (no.) | |
| IgA | 4 (9.5%) |
| IgD | 3 (7.1%) |
| IgG | 19 (45.2%) |
| Light chain only | 16 (38.1%) |
| Light chain (no.) | |
| Kappa | 22 (52.4%) |
| Lambda | 20 (47.6%) |
| International staging system (no.) | |
| Stage I | 7 (16.7%) |
| Stage II | 20 (47.6%) |
| Stage III | 15 (35.7%) |
| Laboratory findings | |
| Bone marrow plasma cell (%) | 39.7 ± 29.7 |
| Serum M-protein (g/dL) | 2.1 ± 2.6 |
| Urine M-protein (mg/dL) | 827.9 ± 2549.0 |
| Serum FLC ratio† | 458.9 ± 736.0 |
| Absolute FLC difference (mg/L) | 3880.7 ± 5612.6 |
| Beta-2 microglobulin (ug/mL) | 7.3 ± 8.8 |
| Albumin (g/dL) | 3.3 ± 0.7 |
| Calcium (mg/dL) | 9.3 ± 1.6 |
| Creatinine (mg/dL) | 1.7 ± 1.6 |
| Hemoglobin (g/dL) | 10.3 ± 2.1 |